Prellis Biologics aims to eliminate the wait list for human organ transplants and speed up development of vital new drug therapies. Using innovations in 3D printing and stem cell development, Prellis can create tissue and organs with the microvascular systems that are critical for supporting viable human tissue. Based in San Francisco, the company's patent-pending technologies use proven methods in biology, physics, and advanced imaging to revolutionize the field of tissue engineering.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 09/14/17 | $1,800,000 | Seed |
415 Ventures Civilization Ventures True Ventures  | undisclosed |
| 08/01/19 | $8,700,000 | Series A |
IndieBio True Ventures | undisclosed |
